Clinical Trial Update: High Dose Atorvastatin for Preventing Contrast-induced Nephropathy [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update indicates completion of Phase 2 and Phase 3 studies evaluating high-dose atorvastatin for preventing contrast-induced nephropathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Nephropathy

Drugs mentioned

• Lipitor (atorvastatin)

Snippet

Sponsor: Isfahan University of Medical Sciences | Conditions: Contrast-Induced Nephropathy | Phase 2, Phase 3 | Status: COMPLETED